Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Terazosin
Accord Healthcare Limited
G04CA; G04CA03
Terazosin
5 milligram(s)
Tablet
Product subject to prescription which may be renewed (B)
Alpha-adrenoreceptor antagonists; terazosin
Marketed
2009-04-17
PACKAGE LEAFLET: INFORMATION FOR THE USER TERAZOSIN 2 MG TABLETS TERAZOSIN 5 MG TABLETS Terazosin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Terazosin Tablets are and what they are used for 2. What you need to know before you take Terazosin Tablets 3. How to take Terazosin Tablets 4. Possible side effects 5. How to store Terazosin Tablets 6. Contents of the pack and other information 1. WHAT TERAZOSIN TABLETS ARE AND WHAT THEY ARE USED FOR Terazosin belongs to the class of drugs known as alpha-1- selective adrenoreceptor blocking agents. TERAZOSIN TABLETS ARE USED TO: treat patients suffering from high blood pressure. They help reduce blood pressure. treat a condition called benign prostatic hyperplasia which is common in older men. This condition is caused by the prostate gland growing too big and obstructing, it can partially block the flow of urine from the bladder. This leads to some unpleasant symptoms such as: - a weak or interrupted urine flow - a need to pass water more frequently and/or a sudden need to pass water. Terazosin can relax the muscle of the prostate gland and bladder exit to help relieve these symptoms. Ask your doctor or pharmacist if you need additional information. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TERAZOSIN TABLETS DO NOT TAKE TERAZOSIN TABLETS: If you are allergic to active substance, or any of the other ingredients of this medicine (listed in section 6). If you have ever experienced a brief loss of consciousness when passing water, Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Terazosin 5mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg terazosin (as terazosin monohydrochloride dihydrate). Excipient with known effect: Each tablet contains 117.12 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Light pink coloured, round, flat tablets with bevelled edges and score line on one side of the tablet. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Terazosin tablets are indicated for: The treatment of mild to moderate hypertension The symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For oral use. For the different dosage regimens suitable strengths are available. The dose of terazosin should be adjusted according to the patient's response. The following is a guide to administration: INITIAL DOSE The lowest single dose of 1 mg before bedtime for all patients, which should not be exceeded. Strict compliance with this recommendation should be observed to minimise potential acute first-dose hypotensive episodes. SUBSEQUENT DOSES Treatment of mild to moderate hypertension: The single daily dosage may be increased by approximately doubling the dosage at weekly intervals to achieve the desired blood pressure response. The maintenance dose needs to be adjusted to the patient’s response. 2 mg/day may be sufficient with increases up to 10 mg if necessary (clinical studies support the use of 2 – 10 mg as maintenance dose). H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Read the complete document